Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

JSPRBullishM&Anews

High materiality8/10

Jasper to Acquire Kira for $132M Financing; Pipeline Milestones Through 2028

Jul 16, 2026, 5:17 PM EDT2 sourcesAI-analyzed

Why it may matterVerify against the original reporting

The merger creates a larger, diversified pipeline with a clear funding runway and near-term catalysts (KP-104, KP-701, briquilimab milestones). The upfront financing and out-licensing reduce near-term capital needs, which can support a positive re-rating, despite dilution from the equity-heavy deal.

AI summary

What happened, with direct paths to the underlying reporting

Jasper Therapeutics announced an all-stock acquisition of Kira Pharmaceuticals, paired with a private placement of about $132 million. The combined company out-licenses KP-301 and KP-402 to Mirador for $12 million upfront, funding operations through late-2028. The move expands the portfolio toward KP-104, briquilimab and KP-701, setting up multiple clinical milestones through 2027–2028.

Jasper completes acquisition of Kira; $132M private placement funds through 2028.
KP-301 and KP-402 out-licensed to Mirador for $12M upfront.
Combined pipeline emphasizes KP-104, briquilimab, KP-701; multiple milestones through 2028.
Post-close ownership: Kira holders ~49.9%, Jasper ~6.7%, private placement ~43.5%.
Pro-forma cash runway through 2H 2028; multiple clinical milestones highlighted.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Jasper to Acquire Kira for $132M Financing; Pipeline Milestones Through 2028

Jasper Therapeutics Shares Fall On Briquilimab Drug Lot Problem

Why Is Chronic Disease-Focused Jasper Therapeutics Stock Trading Higher On Monday?